News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,950 Results
Type
Article (41411)
Company Profile (203)
Press Release (689320)
Multimedia
Podcasts (92)
Webinars (14)
Section
Business (209892)
Career Advice (1935)
Deals (35139)
Drug Delivery (116)
Drug Development (79797)
Employer Resources (155)
FDA (16094)
Job Trends (15383)
News (348741)
Policy (32966)
Tag
Academia (2745)
Accelerated approval (23)
Adcomms (26)
Allergies (134)
Alliances (46412)
ALS (167)
Alzheimer's disease (1694)
Antibody-drug conjugate (ADC) (292)
Approvals (16266)
Artificial intelligence (515)
Autoimmune disease (125)
Automation (33)
Bankruptcy (332)
Best Places to Work (12324)
BIOSECURE Act (23)
Biosimilars (184)
Biotechnology (141)
Bladder cancer (148)
Brain cancer (58)
Breast cancer (602)
Cancer (4601)
Cardiovascular disease (400)
Career advice (1577)
Career pathing (24)
CAR-T (278)
CDC (36)
Cell therapy (749)
Cervical cancer (36)
Clinical research (67810)
Collaboration (1572)
Company closure (4)
Compensation (1056)
Complete response letters (57)
COVID-19 (2499)
CRISPR (89)
C-suite (730)
Cystic fibrosis (143)
Data (5770)
Decentralized trials (2)
Denatured (22)
Depression (126)
Diabetes (478)
Diagnostics (7049)
Digital health (42)
Diversity (7)
Diversity, equity & inclusion (40)
Drug discovery (242)
Drug pricing (162)
Drug shortages (30)
Duchenne muscular dystrophy (213)
Earnings (98959)
Editorial (53)
Employer branding (21)
Employer resources (125)
Events (128782)
Executive appointments (1006)
FDA (18907)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (20)
Funding (1404)
Gene editing (194)
Generative AI (46)
Gene therapy (580)
GLP-1 (1004)
Government (4995)
Grass and pollen (8)
Guidances (379)
Healthcare (20670)
HIV (50)
Huntington's disease (42)
IgA nephropathy (80)
Immunology and inflammation (267)
Immuno-oncology (35)
Indications (76)
Infectious disease (2762)
Inflammatory bowel disease (196)
Inflation Reduction Act (13)
Influenza (109)
Intellectual property (215)
Interviews (327)
IPO (17191)
IRA (50)
Job creations (3426)
Job search strategy (1377)
Kidney cancer (16)
Labor market (82)
Layoffs (602)
Leadership (17)
Legal (7734)
Liver cancer (93)
Longevity (13)
Lung cancer (637)
Lymphoma (357)
Machine learning (36)
Management (44)
Manufacturing (698)
MASH (159)
Medical device (14710)
Medtech (14749)
Mergers & acquisitions (18992)
Metabolic disorders (1210)
Multiple sclerosis (148)
NASH (20)
Neurodegenerative disease (305)
Neuropsychiatric disorders (80)
Neuroscience (2852)
NextGen: Class of 2025 (7096)
Non-profit (5038)
Now hiring (46)
Obesity (569)
Opinion (247)
Ovarian cancer (153)
Pain (182)
Pancreatic cancer (198)
Parkinson's disease (270)
Partnered (25)
Patents (461)
Patient recruitment (397)
Peanut (58)
People (57923)
Pharmaceutical (45)
Pharmacy benefit managers (26)
Phase I (21187)
Phase II (30012)
Phase III (22534)
Pipeline (3794)
Policy (237)
Postmarket research (2196)
Preclinical (8945)
Press Release (71)
Prostate cancer (225)
Psychedelics (46)
Radiopharmaceuticals (280)
Rare diseases (759)
Real estate (5770)
Recruiting (60)
Regulatory (24156)
Reports (55)
Research institute (2498)
Resumes & cover letters (340)
Rett syndrome (22)
RNA editing (11)
RSV (81)
Schizophrenia (144)
Series A (232)
Series B (176)
Service/supplier (9)
Sickle cell disease (97)
Special edition (26)
Spinal muscular atrophy (162)
Sponsored (31)
Startups (3359)
State (2)
Stomach cancer (17)
Supply chain (101)
Tariffs (65)
The Weekly (69)
Vaccines (946)
Venture capital (72)
Weight loss (389)
Women's health (68)
Worklife (13)
Date
Today (108)
Last 7 days (665)
Last 30 days (2743)
Last 365 days (32519)
2025 (31559)
2024 (37312)
2023 (42382)
2022 (53017)
2021 (57342)
2020 (56695)
2019 (50584)
2018 (37410)
2017 (33677)
2016 (33120)
2015 (38525)
2014 (31629)
2013 (26798)
2012 (28035)
2011 (28758)
2010 (25653)
Location
Africa (748)
Alabama (85)
Alaska (7)
Arizona (252)
Arkansas (14)
Asia (43340)
Australia (7092)
California (10600)
Canada (3140)
China (1025)
Colorado (446)
Connecticut (469)
Delaware (312)
Europe (97309)
Florida (1571)
Georgia (345)
Hawaii (2)
Idaho (63)
Illinois (830)
India (59)
Indiana (510)
Iowa (20)
Japan (371)
Kansas (121)
Kentucky (39)
Louisiana (25)
Maine (81)
Maryland (1376)
Massachusetts (7836)
Michigan (326)
Minnesota (615)
Mississippi (6)
Missouri (130)
Montana (34)
Nebraska (26)
Nevada (117)
New Hampshire (80)
New Jersey (2917)
New Mexico (31)
New York (2851)
North Carolina (1475)
North Dakota (10)
Northern California (5071)
Ohio (324)
Oklahoma (22)
Oregon (42)
Pennsylvania (2158)
Puerto Rico (20)
Rhode Island (44)
South America (1130)
South Carolina (60)
South Dakota (1)
Southern California (4126)
Tennessee (164)
Texas (1644)
United States (38456)
Utah (321)
Vermont (1)
Virginia (254)
Washington D.C. (76)
Washington State (883)
West Virginia (4)
Wisconsin (103)
Wyoming (2)
730,950 Results for "20".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Obesity
Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss
The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst expectations and highlighting a “potentially best in class profile,” according to BMO Capital Markets.
November 6, 2025
·
3 min read
·
Heather McKenzie
Layoffs
Vedanta Downsizes by 20% After Phase II Stumble in Ulcerative Colitis
Vedanta is parting ways with 23 employees, or approximately 20% of its headcount, after Phase II data for microbiome therapy VE202 failed to demonstrate significant response rates in patients with ulcerative colitis.
August 14, 2025
·
2 min read
·
Tristan Manalac
Press Releases
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
December 12, 2025
·
7 min read
Press Releases
Junevity Expands Seed Funding to $20 Million for Cell Reprogramming with siRNA
December 3, 2025
·
3 min read
Layoffs
Biogen Shuffles 20 Staff After Ending AAV Work
The AAV pullback comes amid Biogen’s aggressive cost-cutting campaign, which put some 1,000 jobs on the chopping block with the goal of generating $1 billion in savings by 2025.
September 29, 2025
·
2 min read
·
Tristan Manalac
Press Releases
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
November 14, 2025
·
4 min read
Press Releases
Pharma 4.0 Market Size Worth USD 81.20 Billion By 2034
December 2, 2025
·
1 min read
Press Releases
Scilex Holding Company Announces Exercise of Warrants for $20.3 Million Gross Proceeds
November 24, 2025
·
9 min read
Press Releases
Automated and Closed Cell Therapy Market Size Worth USD 11.20 Bn by 2034
November 24, 2025
·
1 min read
Press Releases
Nanox to Report Third Quarter 2025 Financial Results on November 20, 2025
November 10, 2025
·
1 min read
1 of 73,095
Next
